New Antidepressant Compounds (2)

Currently available antidepressant drugs treat only 70% of persons diagnosed with depressive illness.  These drugs show a profile of blocking reuptake of serotonin and norepinephrine.  Several lines of evidence, including the NIH STAR*D study suggest that addition of a dopamine reuptake-blocking action could treat refractory depressed individuals.  In addition, it is hypothesized that addition of dopamine reuptake blocking action could lead to a faster onset of drug action.  This invention comprises several novel chemical entities that potently inhibit reuptake of all three neurotransmitters (serotonin, norepinephrine, and dopamine).

Patent Information:
Drug Discovery
For Information, Contact:
Rob Whitehead
Senior Licensing Manager
Virginia Tech Intellectual Properties, Inc.
(540) 443-9219
Paul Carlier
Christopher Monceaux
Tom Simpson
Mike Wood
Mark Chapdelaine
Dan Hill
Jim Kang
Jim Woods
Elliott Richelson
Abdul Fauq
Dola Sinha